Kompozisyon:
Tedavide kullanılır:
Fedorchenko Olga Valeryevna tarafından tıbbi olarak gözden geçirilmiştir, Eczane Son güncelleme: 09.04.2022
Dikkat! Sayfadaki bilgiler sadece sağlık profesyonelleri içindir! Bilgi kamu kaynaklarında toplanır ve anlamlı hatalar içerebilir! Dikkatli olun ve bu sayfadaki tüm bilgileri tekrar kontrol edin!
Aynı bileşenlere sahip en iyi 20 ilaç:
Mirax-M Süspansiyon yetişkinlerde ve çocuklarda bulantı ve kusma semptomlarının giderilmesi için endikedir.
Mirax-M Oral Süspansiyon, bulantı ve kusmayı kontrol etmek için gereken en kısa süre boyunca en düşük etkili dozda kullanılmalıdır.
Yemeklerden önce Mirax-M Oral Süspansiyon almanız önerilir. Yemeklerden sonra alınırsa, ilacın emilimi biraz gecikir.
Hastalar her dozu planlanan zamanda almaya çalışmalıdır. Planlanan bir doz kaçırılırsa, kaçırılan doz atlanmalı ve normal dozlama programı devam ettirilmelidir. Kaçırılan bir dozu telafi etmek için doz iki katına çıkarılmamalıdır.
Genellikle, maksimum tedavi süresi bir haftayı geçmemelidir.
Yetişkinler ve ergenler (12 yaş ve üstü ve 35 kg veya daha ağır).
Günde üç defaya kadar günde maksimum 30 ml doz ile 10 ml (1 mg / ml oral süspansiyon).
Yenidoğanlar, bebekler ve çocuklar (12 yaş altı ve 35 kg'dan hafif)
Doz 0.25 mg / kg'dır. Bu, günde üç kez, günde maksimum 0.75 mg / kg doz ile verilmelidir. Örneğin, 10 kg ağırlığındaki bir çocuk için doz 2.5 mg'dır ve bu günde üç kez günde maksimum 7.5 mg'lık bir doza verilebilir.
Karaciğer yetmezliği
Mirax-M Oral Süspansiyon orta veya şiddetli karaciğer yetmezliğinde kontrendikedir. Bununla birlikte, hafif karaciğer yetmezliğinde doz modifikasyonu gerekli değildir.
Böbrek Bozukluğu
Mirax-M'nin eliminasyon yarılanma ömrü şiddetli böbrek yetmezliğinde uzadığından, tekrarlanan uygulamada, Mirax-M Oral Süspansiyonun dozlama sıklığı, bozukluğun şiddetine bağlı olarak günde bir veya iki kez azaltılmalıdır ve doz azaltılmalıdır. Uzun süreli tedavi gören bu hastalar düzenli olarak gözden geçirilmelidir.
Mirax-M suspension is contraindicated in the following situations:
-
- Prolactin-releasing pituitary tumour (prolactinoma).
- When stimulation of the gastric motility could be harmful, e.g. in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.
- In patients with moderate or severe hepatic impairment.
- In patients who have known existing prolongation of cardiac conduction intervals, particularly QTc patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure
- co-administration with QT-prolonging drugs, with the exception of apomorphine
- co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects)
Precautions for use
Renal impairment:
The elimination half-life of Mirax-M is prolonged in severe renal impairment. For repeated administration, the dosing frequency of Mirax-M should be reduced to once or twice daily depending on the severity of the impairment. The dose may also need to be reduced.
Cardiovascular effects:
Mirax-M has been associated with prolongation of the QT interval on the electrocardiogram. During post-marketing surveillance, there have been very rare cases of QT prolongation and torsades de pointes in patients taking Mirax-M. These reports included patients with confounding risk factors, electrolyte abnormalities and concomitant treatment which may have been contributing factors.
Epidemiological studies showed that Mirax-M was associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death. A higher risk was observed in patients older than 60 years, patients taking daily doses greater than 30mg, and patients concurrently taking QT_prolonging drugs or CYP3A4 inhibitors.
Mirax-M should be used at the lowest effective dose in adults and children.
Mirax-M is contraindicated in patients with known existing prolongation of cardiac conduction intervals, particularly QTc, in patients with significant electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia), or bradycardia, or in patients with underlying cardiac diseases such as congestive heart failure due to increased risk of ventricular arrhythmia. Electrolyte disturbances (hypokalaemia, hyperkalaemia, hypomagnesaemia) or bradycardia are known to be conditions increasing the proarrythmic risk.
Treatment with Mirax-M should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should consult their physician.
Patients should be advised to promptly report any cardiac symptoms.
Use in infants:
Although neurological side effects are rare , the risk of neurological side effects is higher in young children since metabolic functions and the blood-brain barrier are not fully developed in the first months of life. Overdosing may cause extrapyramidal symptoms in children, but other causes should be taken into consideration.
Use with Potent CYP3A4 Inhibitors:
Co-administration with oral ketoconazole, erythromycin or other potent CYP3A4 inhibitors that prolong the QTc interval should be avoided.
Co-administration of levodopa:
Although no dosage adjustment of levodopa is deemed necessary, an increase of plasma levodopa concentration (max 30-40%) has been observed when Mirax-M was taken concomitantly with levodopa.
Use with apomorphine:
Mirax-M is contra-indicated with QT prolonging drugs including apomorphine, unless the benefit of the co-administration with apomorphine outweighs the risks, and only if the recommended precautions for co-administration mentioned in the apomorphine SmPC are strictly fulfilled. Please refer to the apomorphine SmPC.
Mirax-M suspension contains 400mg of liquid sorbitol (non-crystallising, E420) per ml, which may have a mild laxative effect. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Mirax-M suspension contains methyl hydroxybenzoate (E218) and propyl hydroxybenzoate (E216), which may cause allergic reactions (possibly delayed).
Mirax-M has no or negligible influence on the ability to drive and use machines.
However, we will provide data for each active ingredient